Genotype-phenotype associations in non-classical steroid 21-hydroxylase deficiency
Abstract
OBJECTIVE: To evaluate whether genotype differences can explain the clinical variability of non-classical steroid 21-hydroxylase deficiency (NC21-OHD) and to determine if genotype is related to ethnic origin. DESIGN: Genotyping for mutations in the steroid 21-hydroxylase (CYP21) gene was performed in 45 unrelated Israeli Jewish patients (nine males) with NC21-OHD (60min 17-hydroxyprogesterone (17-OHP), 45-386nmol/l) who were referred for evaluation of postnatal virilization or true precocious/early puberty. Eleven siblings diagnosed through family screening were genotyped as well. METHODS: Patients were divided by genotype into three groups: (A) homozygous or compound heterozygous for the mild mutations (V281L or P30L) (n=29; eight males); (B) compound heterozygous for one mild and one severe mutation (Q318X, I2 splice, I172N) (n=12; no males); (C) mild mutation detected on one allele only (n=4; one male; peak 17-OHP 58-151nmol/l). We then related the genotype to the ethnic origin, clinical phenotype and hormone level. Since group C was very small, comparisons were made between groups A and B only. RESULTS: At diagnosis, group B tended to be younger (5. 8+/-3.0 vs 8.1+/-4.3 years, P=0.09), had greater height SDS adjusted for mid-parental height SDS (1.6+/-1.1 vs 0.7+/-1.4, P=0.034), tended to have more advanced bone age SDS (2.9+/-1.5 vs 1.7+/-2.1, P=0.10) and had a higher peak 17-OHP level in response to ACTH stimulation (226+/-92 vs 126+/-62nmol/l, P<0.01). Group B also had pubarche and gonadarche at an earlier age (5.1+/-2.4 vs 7.4+/-2.2 years, P<0.01 and 7.4+/-1.8 vs 9.9+/-1.4 years, P<0.001, respectively) and a higher rate of precocious puberty (50 vs 17%, P=0.04). Stepwise logistic regression analysis (excluding males) yielded age at gonadarche as the most significant variable differentiating the two groups, with a positive predictive value of 86% for a cut-off of 7.5 years. CONCLUSIONS: The findings suggest that genotype might explain some of the variability in the phenotypic expression of NC21-OHD. Compound heterozygotes for one mild and one severe mutation have a higher peak 17-OHP associated with pubarche and gonadarche at an earlier age and more frequent precocious puberty. Hence, the severity of the enzymatic defect might determine the timing and pattern of puberty.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The most frequent CYP21A2 mutation in the 55 NCCAH children was V281L.
“The CYP21A2 genotyping of the 55 children affected by NCCAH showed that, as in other series, the most frequently observed mutation is V281L (23,29,30).”
From Relationship of CYP21A2 genotype and serum 17-hydroxyprogesterone and cortisol levels in a large cohort of Italian children with premature pubarche (2011) · cites this paper as [29]
The 52.7% homozygosity for mild mutations is higher than in French adult and Brazilian adult series but similar to pediatric Spanish and Jewish series.
“a percentage strikingly higher than that recently reported in a large series of French adult patients (26) and in previous studies in adult Brazilian patients (23), but similar to the one detected in pediatric Spanish (29) and Jewish patients (30), mostly comprised of children with PP.”
From Relationship of CYP21A2 genotype and serum 17-hydroxyprogesterone and cortisol levels in a large cohort of Italian children with premature pubarche (2011) · cites this paper as [29]
The citation lists haven’t been fetched yet
References 29 · Cited by 59
- Authors
- Weintrob, N., Brautbar, C., Pertzelan, A., Josefsberg, Z., Dickerman, Z., Kauschansky, A., Lilos, P., Peled, D., Phillip, M., & Israel, S.
- Affiliations
- Tel Aviv University (IL)
- Corresponding author
- Weintrob, N
- ORCID
- Phillip, M
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-09-01
- Volume
- 143
- Issue
- 3
- Pages
- 397-403
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2148528270
- Cited by
- 59
- References
- 29
- Citations by year
- 2026: 1 · 2025: 1 · 2023: 4 · 2022: 4 · 2021: 6 · 2020: 2 · 2019: 3 · 2018: 1 · 2017: 4 · 2016: 3 · 2015: 3 · 2014: 2 · 2013: 2 · 2012: 3
- FWCI
- 0.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- genotype-phenotype correlation, 17-hydroxyprogesterone, pubarche, gonadarche, precocious puberty, masculinization, bone age, height, ethnicity, compound heterozygosity, family screening, ACTH stimulation test
- MeSH terms
- Adolescent, Adrenal Hyperplasia, Congenital, Alleles, Anti-Inflammatory Agents, Body Height, Child, Child, Preschool, Female, Genotype, Humans, Hydrocortisone, Infant, Infant, Newborn, Gonadotropin-Releasing Hormone, Male, Mutation, Phenotype, Steroid 21-Hydroxylase, 17-alpha-Hydroxyprogesterone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review